Provenance du réseau au premier degré de Todd Wider
Entité | Type d'entité | Industrie | |
---|---|---|---|
Xanadu Bio Inc.
2
| Private Company | 2 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Todd Wider via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
ABEONA THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member | |
ASP ISOTOPES INC. | Pharmaceuticals: Major | Director/Board Member | |
Boxer Capital LLC
Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California. | Investment Managers | Corporate Officer/Principal | |
The University of Chicago | College/University | Undergraduate Degree | |
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Biotechnology | Director of Finance/CFO | |
IMMUNOME, INC. | Biotechnology | Corporate Officer/Principal | |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | Pharmaceuticals: Major | Founder | |
GENENTA SCIENCE S.P.A. | Pharmaceuticals: Major | Director/Board Member | |
Varian Biopharmaceuticals, Inc.
Varian Biopharmaceuticals, Inc. BiotechnologyHealth Technology Part of Healthtech Solutions, Inc., Varian Biopharmaceuticals, Inc. is a private precision oncology company based in Naples, FL. Varian Bio is developing novel therapeutics for the treatment of cancer using precision oncology, which involves DNA testing to identify genetic mutations in tumors for more targeted treatment recommendations. Varian Bio's lead drug candidate, Var-101, is being developed in a topical formulation for the treatment of basal cell carcinoma, while Var-102, an oral formulation, is being developed for the treatment of various solid tumors, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Varian Bio is also seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. The CEO of the company is Jeffrey Blaine Davis. Varian Biopharmaceuticals was acquired by Healthtech Solutions, Inc. on May 07, 2021. | Biotechnology | Director/Board Member | |
Columbia University College of Physicians & Surgeons | College/University | Doctorate Degree | |
ARYA SCIENCES ACQUISITION CORP V | Financial Conglomerates | Director/Board Member | |
ARYA SCIENCES ACQUISITION CORP IV | Financial Conglomerates | Director/Board Member | |
Wider Film Projects | Corporate Officer/Principal | ||
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | Biotechnology | Chairman | |
Princeton University | College/University | Undergraduate Degree | |
University of Pennsylvania Medical Center | College/University | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 21 |
Italie | 2 |
Sectorielle
Health Technology | 10 |
Finance | 7 |
Consumer Services | 5 |
Technology Services | 2 |
Opérationnelle
Director/Board Member | 13 |
Independent Dir/Board Member | 7 |
Corporate Officer/Principal | 4 |
Founder | 3 |
Doctorate Degree | 2 |
Relations les plus connectées
Insiders | |
---|---|
Todd Wider | 15 |
Bruce Turner | 9 |
- Bourse
- Insiders
- Todd Wider
- Connexions Sociétés